|
Late immune-related adverse events with immune checkpoint inhibitors. |
|
|
Stock and Other Ownership Interests - Merck (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol Myers Squibb Foundation |
Honoraria - Bristol Myers Squibb Foundation |
Speakers' Bureau - Bristol Myers Squibb Foundation |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - eKare Inc. eHMISA |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma |
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Scholar Rock; Seagen; Surface Oncology; Third Rock Ventures; Werewolf Pharma |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme Corp. |